• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
cnb1439_3rs-project_nav-ad_v1
  • About us
  • News
  • Events
  • Careers
cn-bio-organ-on-a-chip-logo
  • Products
    • PhysioMimix® OOC Microphysiological Systems
    • Consumables
      • PhysioMimix® multi-chip plates
      • 3D validated cells
      • NASH-in-a-box
    • Organ-on-a-chip models
    • Gut/Liver-on-a-chip
    • Lung-on-a-chip
    • Support packages
  • Applications
    • Disease modeling
    • Safety toxicology
    • ADME
  • Services
    • Non-Alcoholic Steatohepatitis
    • Drug-Induced Liver Injury
    • ADME
  • Technology
  • Resources
  • Company
    • About us
    • Events
    • News
    • Careers in Biotech
  • Contact us

Explore our solutions


PhysioMimix® is a suite of hardware, consumables and assay protocols that enable you to recreate complex human biology and accurately predict human drug responses.

PhysioMimix OOC

physiomimix-single-and-multi-organ-on-a-chip-systems
Learn more

Consumables

Multi-chip plates
3D validated cells
NASH-in-a-box
Bioavailability assay kit: Human 18
DILI assay kit: Human 24
Learn more

Models

Single-organ models
- Liver-on-a-chip model
- Lung-on-a-chip model
Multi-organ models
- Gut/Liver-on-a-chip models

Support packages

PhysioMimix® support packages

Discover the applications


Investigate the application areas that our PhysioMimix® products and services support

Learn more

Disease modeling

Metabolic dysfunction-associated steatohepatitis
Hepatitis B
Pulmonary infection
Learn more

Safety toxicology

Drug-induced liver injury
Immune-mediated liver injury
Learn more

ADME

Drug absorption
Drug metabolism
Drug bioavailability
Oligonucleotide delivery
Learn more

Studies as a service


Our team will work collaboratively with you to design a study around your research goals and generate actionable data within weeks

Learn more
icon-nash-1-150x150.png MASLD/MASH
icon-dili-tox-150x150.png Drug-induced liver injury
icon-adme-150x150.png ADME

CN Bio to provide drug metabolism and safety toxicity testing services

October 27, 2020

Extended range of services supports accelerated drug discovery and development using predictive 3D Liver-on-Chip technology

CN Bio, a leading 3D cell culture company, that has developed single and multi-organ microphysiological systems (MPS) to improve the accuracy and efficiency of drug discovery, today announced the commercial launch of its Drug Metabolism and Safety Toxicity Testing Services. Liver toxicity is a principal safety concern during drug discovery and development, with the potential to terminate expensive clinical trials already underway. The new services will incorporate the Company’s advanced Liver-on-Chip™ technology, and expertise in the field to enable researchers to generate predictive and human-relevant data, improving the translatability from discovery to clinic, and accelerating new drugs to market.

Based on the success of CN Bio’s Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) Fee-For-Service offerings, the new toxicity testing services also provide researchers with additional support and bandwidth during the COVID-19 pandemic, when laboratories are not at full capacity. Similarly to the NAFLD/NASH Fee-For-Service, all studies use the Company’s PhysioMimix® Organ-on-Chip system and in vitro 3D Liver-on-Chip™ model; replicating the physiological and mechanical microenvironment of the liver to fast-track lead targets and generate actionable data in weeks that is reproducible, and cost-effective versus animal studies.

CN Bio’s extended portfolio of services offers solutions to many existing workflow challenges including: drug metabolism testing, to study the human metabolism of lead candidates, identify metabolites and correlation with cell health – even for low clearance compounds, and safety toxicity testing, to provide in-depth analysis of acute or chronic drug-induced liver injury using a wide range of endpoints to determine causality and mechanism of toxicity. The Company also provides complimentary service capabilities to support industry and biotechnology organisations that have been impacted by the COVID-19 pandemic.

Dr David Hughes, CEO, CN Bio, said: “One in ten drugs successfully reach clinical trials, with safety concerns being the principal cause for subsequent failure. Through our enhanced drug metabolism and safety toxicity testing services, we enable scientists to take a step beyond what is currently possible with 2D cell culture and animal studies to improve their chances of clinical success. Our technologies are on the cutting-edge of research to simulate human biological conditions, in vitro, and we are confident in our ability to support customers in developing tomorrow’s medicines, especially at this challenging time.”

For more information about CN Bio’s services, visit: https://cn-bio.com/drug-metabolism-and-safety-toxicity-testing-services/

Category iconPress releases

Primary Sidebar

Other recent news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
  • CN Bio introduces cross-species DILI services to enhance in vitro to in vivo extrapolation during preclinical drug development June 10, 2025
  • CN Bio expands access to OOC solutions for APAC customers with distributor agreement in South Korea May 20, 2025

Speak to our experts

Request a meeting with one of our OOC experts to see how our products and services can support your studies

Request a meeting

Footer

CN Bio logo

332 Cambridge Science Park, Milton Road
Cambridge, CB4 0WN

UK: +44 (0) 1223 737 941

US: +1 415 523 4005

Privacy | Cookies | Regulatory | Accessibility
Website terms | Terms of sale

Product Recycling

©2025 CN Bio Innovations Ltd
Registered No. ‍06517359. VAT No. GB978184563

Latest news

  • Integrating In Silico Tools with Organ-on-a-Chip to advance ADME studies July 15, 2025
  • NIH to prioritize human-based research technologies & reduce animal use in research July 7, 2025
  • CN Bio to participate in 3Rs Collaborative-lead project with FDA to build confidence in Liver MPS for DILI June 25, 2025
Cyber Essentials Logo